p40 inhibitor - Angelini
Latest Information Update: 11 Jun 2015
At a glance
- Originator Angelini Group
- Mechanism of Action Interleukin 12 subunit p40 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Discontinued Psoriasis